Area of research
Psychiatry and Mental health · Physiology · test8
Research interest
Research interests include Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Systemic Lupus Erythematosus Research, and Medical Imaging Techniques and Applications.
Sex differences in amyloid PET in a large, real‐world sample from the Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) Study
Patients with anti-SAE+ dermatomyositis display refractory and difficult-to-treat skin manifestations: case series from two Italian cohorts and review of literature.
Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model
Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)
Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment
The interferon in idiopathic inflammatory myopathies: Different signatures and new therapeutic perspectives. A literature review
Robustness of CSF Aβ42/40 and Aβ42/P‐tau181 measured using fully automated immunoassays to detect AD‐related outcomes
The Sporadic Early‐onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) Cohort
Sex and <i>APOE ε4</i> carrier effects on atrophy, amyloid PET, and tau PET burden in early‐onset Alzheimer's disease
Profiling baseline performance on the Longitudinal Early‐Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection
Cerebrospinal fluid biomarkers in the Longitudinal Early‐onset Alzheimer's Disease Study
The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review
Altered excitatory and inhibitory neuronal subpopulation parameters are distinctly associated with tau and amyloid in Alzheimer’s disease
Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer’s disease
Multi-Modal Biomarkers of Repetitive Head Impacts and Traumatic Encephalopathy Syndrome: A Clinicopathological Case Series
Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI
Quantification of amyloid beta and tau PET without a structural MRI
Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology
PO.6.133 Dynamical trajectory of glucocorticoid tapering and discontinuation in real-world patients with newly diagnosed systemic lupus erythematosus: the gulp study
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease
Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer’s disease
The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS): Framework and methodology
Multimodal neuroimaging of sex differences in cognitively impaired patients on the Alzheimer's continuum: greater tau-PET retention in females
rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data
POS0693 EFFICACY AND SAFETY OF BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS IN REAL-LIFE SETTING: RESULTS FROM A LARGE, NATIONWIDE, MULTICENTRIC, PROSPECTIVE COHORT
Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET
18F-flortaucipir PET to autopsy comparisons in Alzheimer’s disease and other neurodegenerative diseases
Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment